Biolife Solutions Inc. (BLFS)
BioLife Is Cleaning Ship
BioLife was overextended on acquisitions, leading to margin compression and dilution of shareholder capital. The company has divested from non-core businesses, focusing on preservation media where it is a market leader. Improved financial results include gross margin expansion, lower OpEx, and increased revenue guidance, driven by growth in the Cell Processing business.
BioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Rod de Greef – Chairman and Chief Executive Officer Garrie Richardson – Chief Revenue Officer Conference Call Participants Jacob Johnson – Stephens Anna Snopkowski – KeyBanc Matt Stanton – Jefferies Steven Mah – TD Cowen Thomas Flaten – Lake Street Capital Markets Operator Good afternoon, and welcome to the BioLife Solutions Q2 2024 Shareholder and Analyst Conference Call. [Operator Instructions] Please note, this event is being recorded.
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago.
What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing'
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
